Lincoln Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹191 Cr +17.2% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
LP

Lincoln Pharmaceuticals Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Lincoln Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹177Cr
+14.9% YoY
−5.3% QoQ
Net profit
₹36Cr
+28.6% YoY
+200% QoQ
Margin
15%
0 pp YoY
+2 pp QoQ

Based on Lincoln Pharmaceuticals Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹595
Market cap₹1.2K Cr
P/E12.6

The short version

EBITDA: ₹26.6 crore, up 41% year-on-year - Operating Margin: 19.3%, up by 320 basis points (bps) year-on-year - Profit after Tax (PAT): ₹15.7 crore, up 36% year-on-year - Margin Outlook: The presentation explicitly states a focus on sustaining and improving margins going forward, aiming to maintain operating margin expansion driven by cost optimization and profitable product mix.

From Lincoln Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

See what Lincoln Pharmaceuticals Ltd said on revenue & sales performance — free account, 30 seconds.

Profitability & Margins

See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Lincoln Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Lincoln Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Lincoln Pharmaceuticals Ltd Q1 FY27 results — key figures

Lincoln Pharmaceuticals Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue177154+14.9%187-5.3%
Operating profit (EBITDA)2724+12.5%25+8%
Operating margin15%15%0 pp13%+2 pp
Profit before tax4835+37.1%17+182.4%
Net profit (PAT)3628+28.6%12+200%
EPS (₹)18.0913.82+30.9%5.81+211.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹191 Cr, net profit ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Lincoln Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Lincoln Pharmaceuticals Ltd Q1 FY27 results?

EBITDA: ₹26.6 crore, up 41% year-on-year - Operating Margin: 19.3%, up by 320 basis points (bps) year-on-year - Profit after Tax (PAT): ₹15.7 crore, up 36% year-on-year - Margin Outlook: The presentation explicitly states a focus on sustaining and improving margins going forward, aiming to maintain operating margin expansion driven by cost optimization and profitable product mix.

What is Lincoln Pharmaceuticals Ltd share price analysis?

Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.